Moderna (MRNA) Profit After Tax (2017 - 2026)

Moderna (MRNA) has 10 years of Profit After Tax data on file, last reported at -$1.3 billion in Q1 2026.

• Profit After Tax for Q1 2026 came in at -$1.3 billion, down 38.31% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.2 billion (up 4.86% YoY), and the FY2025 annual result was -$2.8 billion, up 20.75% from the prior year.
• Profit After Tax retreated to -$1.3 billion in Q1 2026 per MRNA's latest filing, from -$826.0 million in the prior quarter.
• Over five years, Profit After Tax peaked at $3.7 billion in Q1 2022 and troughed at -$3.6 billion in Q3 2023.
• A 5-year average of -$239.9 million and a median of -$825.0 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax soared 199.51% in 2022, then plunged 1638.46% in 2025.
• A 5-year view of Profit After Tax shows it stood at $1.5 billion in 2022, then plunged by 85.19% to $217.0 million in 2023, then slumped by 616.13% to -$1.1 billion in 2024, then gained by 26.25% to -$826.0 million in 2025, then plunged by 62.59% to -$1.3 billion in 2026.
• Business Quant data shows MRNA's Profit After Tax at -$1.3 billion in Q1 2026, -$826.0 million in Q4 2025, and -$200.0 million in Q3 2025.